Case Study: Supporting the Clinical Development of a Novel Targeted Oncology Therapy
The Challenge
An EU-based biotech developing a novel targeted oncology therapy was progressing through its Phase I clinical trial but faced several key challenges:
- Limited in-house oncology expertise made it difficult to interpret early clinical data and define the optimal development strategy.
- Phase I was already underway, requiring experienced support without disrupting ongoing activities.
- The company needed to maximise the programme’s potential while carefully managing clinical, regulatory and development risks.
The Solution
tranScrip assembled a bespoke multidisciplinary team that integrated with the biotech’s existing Chemistry, Manufacturing and Controls (CMC) and non-clinical teams.
The team included:
- Clinical Leader to oversee the overall clinical development strategy
- Medical Oncologist providing specialist oncology expertise
- Safety Physician responsible for patient safety oversight and adverse event management
- Biostatistics Expert for data analysis and interpretation
- Regulatory Specialists managing interactions with regulatory authorities
- Preclinical Immunologist linking preclinical findings with clinical development
- Medical Writers producing high-quality regulatory documentation
- Medical Affairs specialists supporting future launch planning and scientific engagement
As the programme progressed successfully, the biotech expanded its internal capabilities, allowing external support to be scaled back as appropriate.
The Outcome
The collaboration resulted in the successful design and execution of a comprehensive clinical development programme.
Clinical Development
- Interpreted and reported extended Phase I clinical data
- Published Phase I findings in a leading oncology journal, increasing scientific visibility
- Designed a robust pivotal study, including both the study synopsis and full clinical protocol
Regulatory Success
- Supported successful End-of-Phase I (EOPI) and End-of-Phase II (EOPII) meetings with the FDA and CHMP
- Ensured regulatory alignment to support progression into later-stage development
Operational Delivery
- Assisted with the selection and management of a Contract Research Organisation (CRO)
- Supported efficient implementation of the pivotal clinical trial
Commercial Readiness
- Developed early market preparation strategies
- Facilitated engagement with key opinion leaders (KOLs) and potential commercial partners
Investment & Partnering
- Helped communicate the programme’s value to investors and strategic partners
- Supported successful fundraising activities and partnership discussions
The Impact
By providing a tailored team of experienced specialists, tranScrip enabled the biotech to confidently interpret and act on its Phase I data while establishing a clear path towards later-stage clinical development.
The partnership reduced the risks associated with limited internal oncology expertise, strengthened regulatory and clinical strategy, and positioned the novel targeted oncology therapy for continued development and future commercial success.
Planning your next clinical milestone?
Whether you’re advancing a first-in-class therapy or preparing for your next regulatory interaction, tranScrip can provide the strategic expertise and flexible support to help move your programme forward.
Get in touch to discuss how we can support your development programme: info@transcrip-group.com